Unilever has raised its full-year guidance after posting its strongest volume growth in more than ten years. The Anglo-Dutch consumer giant, whose portfolio spans Dove, Vaseline, and a beauty division that has been quietly restructured, is betting that momentum can carry into 2027.
Beauty and personal care led the acceleration. The division, which accounts for roughly a fifth of group turnover, has been the beneficiary of a deliberate portfolio tilt toward prestige skin care and clinical positioning, moving the mix away from commodity categories.
The raised outlook comes with a caveat: emerging-market volatility and currency swings remain live risks. But after a decade of hand-wringing over whether the conglomerate model could survive, Unilever is quietly demonstrating that scale, when managed tightly, still compounds.
The numbers mark a turning point. After years of price-led growth that squeezed shoppers and invited private-label competition, Unilever’s latest quarter shows volumes leading — a sign that the group’s premiumisation strategy is translating into actual unit sales.
For the beauty industry, Unilever’s trajectory is a weathervane. If the world’s largest mass-beauty player can grow units in a flat global market, the category’s resilience argument strengthens — and the pressure on rivals like Beiersdorf and L’Oréal’s mass divisions intensifies.
